☰

Katherine S. Pawelczak, Ph.D. - Publications

Affiliations: 
2010 Biochemistry and Molecular Biology Indiana University, Bloomington, Bloomington, IN, United States 
Area:
Biochemistry
Tree Info Grants Similar researchers PubMed Report error

27 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Mendoza-Munoz PL, Gavande NS, VanderVere-Carozza PS, Pawelczak KS, Dynlacht JR, Garrett JE, Turchi JJ. Ku-DNA binding inhibitors modulate the DNA damage response in response to DNA double-strand breaks. Nar Cancer. 5: zcad003. PMID 36755959 DOI: 10.1093/narcan/zcad003  0.752
2022 Turchi JJ, Pawelczak KS, Weinfeld M, McHugh PJ. Editorial: Targeting DNA repair and the DNA damage response: Beyond the standard PI3 kinase-like kinases. Frontiers in Oncology. 12: 1023500. PMID 36237323 DOI: 10.3389/fonc.2022.1023500  0.797
2022 Kelm JM, Samarbakhsh A, Pillai A, VanderVere-Carozza PS, Aruri H, Pandey DS, Pawelczak KS, Turchi JJ, Gavande NS. Recent Advances in the Development of Non-PIKKs Targeting Small Molecule Inhibitors of DNA Double-Strand Break Repair. Frontiers in Oncology. 12: 850883. PMID 35463312 DOI: 10.3389/fonc.2022.850883  0.837
2022 VanderVere-Carozza PS, Gavande NS, Jalal SI, Pollok KE, Ekinci E, Heyza J, Patrick SM, Masters A, Turchi JJ, Pawelczak KS. Targeting Replication Protein A for Cancer Therapy. Frontiers in Oncology. 12: 826655. PMID 35251993 DOI: 10.3389/fonc.2022.826655  0.743
2021 Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, Krais J, VanderVere-Carozza PS, Pawelczak KS, Calvo J, Panzarino NJ, Turchi JJ, Johnson N, Jonkers J, Rothenberg E, et al. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Molecular Cell. 81: 3227. PMID 34358459 DOI: 10.1016/j.molcel.2021.07.015  0.608
2021 Par S, Vaides S, VanderVere-Carozza PS, Pawelczak KS, Stewart J, Turchi JJ. OB-Folds and Genome Maintenance: Targeting Protein-DNA Interactions for Cancer Therapy. Cancers. 13. PMID 34283091 DOI: 10.3390/cancers13133346  0.781
2021 Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, Krais J, VanderVere-Carozza PS, Pawelczak KS, Calvo J, Panzarino NJ, Jonkers J, Johnson N, Turchi JJ, Rothenberg E, et al. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Molecular Cell. PMID 34216544 DOI: 10.1016/j.molcel.2021.06.011  0.69
2020 Gavande NS, VanderVere-Carozza PS, Pawelczak KS, Mendoza-Munoz P, Vernon TL, Hanakahi LA, Summerlin M, Dynlacht JR, Farmer AH, Sears CR, Nasrallah NA, Garrett J, Turchi JJ. Discovery and development of novel DNA-PK inhibitors by targeting the unique Ku-DNA interaction. Nucleic Acids Research. PMID 33119767 DOI: 10.1093/nar/gkaa934  0.857
2020 Sriramkumar S, Matthews TD, Ghobashi AH, Miller SA, VanderVere-Carozza PS, Pawelczak KS, Nephew KP, Turchi JJ, O'Hagan HM. Platinum-Induced Ubiquitination of Phosphorylated H2AX by RING1A is Mediated by Replication Protein A in Ovarian Cancer. Molecular Cancer Research : McR. PMID 32801161 DOI: 10.1158/1541-7786.Mcr-20-0396  0.831
2020 Gavande NS, VanderVere-Carozza PS, Pawelczak KS, Vernon TL, Jordan MR, Turchi JJ. Structure-Guided Optimization of Replication Protein A (RPA)-DNA Interaction Inhibitors. Acs Medicinal Chemistry Letters. 11: 1118-1124. PMID 32550990 DOI: 10.1021/Acsmedchemlett.9B00440  0.835
2019 Turchi JJ, VanderVere-Carozza PS, Gavande NS, Pawelczak KS. Abstract 1301: Targeting protein-DNA interactions in the DNA damage response: Lead identification and optimization for novel inhibitors of RPA and Ku Cancer Research. 79: 1301-1301. DOI: 10.1158/1538-7445.Am2019-1301  0.867
2019 Turchi J, Pawelczak KS, Gavande N, VanderVere-Carozza PS. Abstract A095: Targeting protein-DNA interactions in the DNA damage response: Lead identification and optimization for novel inhibitors of RPA and Ku Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A095  0.863
2018 Turchi JJ, Gavande N, VanderVere-Carozza PS, Vernon T, Pawelczak KS. Abstract LB-A11: Targeting DNA-PK and the DNA damage response via small molecule Ku inhibitors Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Lb-A11  0.876
2017 Pawelczak KS, Gavande NS, VanderVere-Carozza PS, Turchi JJ. Modulating DNA Repair Pathways to Improve Precision Genome Engineering. Acs Chemical Biology. PMID 29210569 DOI: 10.1021/Acschembio.7B00777  0.799
2017 Gavande NS, VanderVere-Carozza P, Mishra AK, Vernon TL, Pawelczak KS, Turchi JJ. Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Protein-DNA Interaction. Journal of Medicinal Chemistry. PMID 28933851 DOI: 10.1021/Acs.Jmedchem.7B00780  0.782
2017 Pawelczak KS, Gavande N, VanderVere-Carozza P, Turchi J. Abstract B34: Development of novel small molecule inhibitors targeting DNA repair proteins Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-B34  0.835
2017 Turchi JJ, Gavande N, VanderVere-Carozza P, Vernon T, Pawelczak K. Abstract LB-119: Targeting DNA-PK via small molecule inhibitors of the Ku-DNA interaction Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-119  0.881
2017 Gavande NS, VanderVere-Carozza PS, Vernon TL, Pawelczak K, Turchi JJ. Abstract 1416: Development of small molecule inhibitors for cancer therapy by targeting RPA and XPA nucleotide excision repair proteins Cancer Research. 77: 1416-1416. DOI: 10.1158/1538-7445.Am2017-1416  0.666
2016 Gavande NS, VanderVere-Carozza PS, Hinshaw HD, Jalal SI, Sears CR, Pawelczak KS, Turchi JJ. DNA repair targeted therapy: The past or future of cancer treatment? Pharmacology & Therapeutics. PMID 26896565 DOI: 10.1016/J.Pharmthera.2016.02.003  0.855
2014 Fang F, Munck J, Tang J, Taverna P, Wang Y, Miller DF, Pilrose J, Choy G, Azab M, Pawelczak KS, VanderVere-Carozza P, Wagner M, Lyons J, Matei D, Turchi JJ, et al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6504-16. PMID 25316809 DOI: 10.1158/1078-0432.Ccr-14-1553  0.711
2013 Tang J, Fang F, Wang Y, Taverna P, Miller DFB, Choy G, Azab M, Matei D, Pawelczak KS, VanderVere-Carozza P, Wagner M, Turchi JJ, Nephew KP. Abstract 4623: The novel, small molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Cancer Research. 73: 4623-4623. DOI: 10.1158/1538-7445.Am2013-4623  0.726
2012 Bennett SM, Woods DS, Pawelczak KS, Turchi JJ. Multiple protein-protein interactions within the DNA-PK complex are mediated by the C-terminus of Ku 80. International Journal of Biochemistry and Molecular Biology. 3: 36-45. PMID 22509479  0.801
2011 Pawelczak KS, Bennett SM, Turchi JJ. Coordination of DNA-PK activation and nuclease processing of DNA termini in NHEJ. Antioxidants & Redox Signaling. 14: 2531-43. PMID 20698792 DOI: 10.1089/Ars.2010.3368  0.85
2010 Pawelczak KS, Turchi JJ. Purification and characterization of exonuclease-free Artemis: Implications for DNA-PK-dependent processing of DNA termini in NHEJ-catalyzed DSB repair. Dna Repair. 9: 670-7. PMID 20347402 DOI: 10.1016/J.Dnarep.2010.03.002  0.796
2008 Pawelczak KS, Turchi JJ. A mechanism for DNA-PK activation requiring unique contributions from each strand of a DNA terminus and implications for microhomology-mediated nonhomologous DNA end joining. Nucleic Acids Research. 36: 4022-31. PMID 18515838 DOI: 10.1093/Nar/Gkn344  0.855
2008 Rahal EA, Henricksen LA, Li Y, Turchi JJ, Pawelczak KS, Dixon K. ATM mediates repression of DNA end-degradation in an ATP-dependent manner. Dna Repair. 7: 464-75. PMID 18207464 DOI: 10.1016/J.Dnarep.2007.12.003  0.749
2005 Pawelczak KS, Andrews BJ, Turchi JJ. Differential activation of DNA-PK based on DNA strand orientation and sequence bias. Nucleic Acids Research. 33: 152-61. PMID 15640450 DOI: 10.1093/nar/gki157  0.84
Show low-probability matches.